High Mobility Group Protein B1 Is an Activator of Apoptotic Response to Antimetabolite Drugs

High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs.

We explored the role of a chromatin-associated nuclear protein high mobility group protein B1 (HMGB1) in apoptotic response to widely used anticancer drugs. A murine fibroblast model system generated from Hmgb1(+)(/)(+) and Hmgb1(-/-) mice was used to assess the role of HMGB1 protein in cellular response to anticancer nucleoside analogs and precursors, which act without destroying the integrity...

High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists.

Plasmacytoid dendritic cells (PDC) are innate immune effector cells that are recruited to sites of chronic inflammation, where they modify the quality and nature of the adaptive immune response. PDCs modulate adaptive immunity in response to signals delivered within the local inflammatory milieu by pathogen- or damage-associated molecular pattern, molecules, and activated immune cells (includin...

Response to TLR9 Agonists the Human Plasmacytoid Dendritic Cell High Mobility Group B1 Protein Suppresses

Phagocytosis of Apoptotic Neutrophils High Mobility Group Protein-1 Inhibits

High mobility group protein B1 is a predictor of poor survival in ovarian cancer

High-mobility group protein B1 (HMGB1) has been implicated in numerous tumour types where expression regulates tumour cell growth and survival. We hypothesised that high HMGB1 expression in ovarian tumours would predict poor patient survival. Using tissue microarrays of primary ovarian cancers combined with a comprehensive database of clinicopathological variables, the expression of HMGB1 was a...